{"filings":[{"id":1303716,"accession_number":"0001178253-26-000021","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-06-26T20:01:32+00:00","items":["5.03","5.07","8.01","9.01"],"status":"ready","headline":"SCYNEXIS increases authorized common shares to 60M (pre-split); resale S-3 registration activated warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 18.75M to 60M (pre-split) via Certificate of Amendment, approved at June 25 annual meeting.","Stockholders approved amendment to 2024 Equity Incentive Plan adding 9.6M pre-split shares (1.2M post-split).","Resale registration on Form S-3 (effective May 8) covers up to 87M pre-split shares, including 43.5M from common warrants exercisable at $1.20/share (pre-split).","Common warrants became exercisable upon the increase in authorized shares, potentially providing proceeds at $1.20/share (pre-split).","Share counts reflect pre-1-for-8 reverse split; post-split numbers are one-eighth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":746358,"accession_number":"0001178253-26-000017","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-05-29T20:01:37+00:00","items":["5.03","9.01"],"status":"ready","headline":"SCYNEXIS effects 1:8 reverse stock split; authorized shares cut to 18.75M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Effective May 29, 2026, every 8 outstanding shares converted into 1 share; par value stays $0.001.","Authorized common shares reduced from 150,000,000 to 18,750,000.","No fractional shares issued; eligible stockholders receive cash in lieu.","Split-adjusted trading on Nasdaq begins June 1, 2026 under ticker SCYX; new CUSIP 811292309.","Reverse split also adjusts stock options, RSUs, and warrants with proportional exercise price changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609918,"accession_number":"0001178253-26-000014","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-05-22T20:20:18+00:00","items":["5.07","8.01"],"status":"ready","headline":"SCYNEXIS stockholders approve 1-for-8 reverse stock split; effective May 29","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved at 1:8 ratio; authorized shares reduced from 150M to 18.75M.","Special meeting results: 44.8 million votes for, 6.7 million against, 0.1 million abstained.","Effective May 29, 2026; trading on Nasdaq on split-adjusted basis starts June 1, 2026.","No fractional shares issued; cash payment in lieu for fractional interests.","New CUSIP 811292 309; ticker symbol SCYX unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91697,"accession_number":"0001178253-26-000009","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Steven C. Gilman to retire from SCYNEXIS Board at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven C. Gilman notified SCYNEXIS Board on April 16, 2026 of intent to retire and not stand for reelection.","Gilman's term ends at the 2026 annual meeting; he remains Compensation Committee Chair and Nominating & Governance member until then.","Resignation not due to any disagreement with Company's operations, policies, strategy, management, or Board.","Management and Board thanked Gilman for his years of service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101949,"accession_number":"0001193125-26-134476","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SCYNEXIS discusses asset acquisition in corporate update call","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Conference call held on March 31, 2026 covering an asset acquisition transaction.","Slide presentation filed as Exhibit 99.1; no financial terms disclosed in this 8-K.","Company's deck highlights focus on severe rare disease solutions.","No specific revenue, earnings, or closing timeline provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101948,"accession_number":"0001193125-26-133259","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"SCYNEXIS raises ~$40M in private placement; extends cash runway into mid-2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$40M from sale of 34.75M shares and 8.75M pre-funded warrants at $0.92 per unit; up to $52.2M additional if warrants exercised.","Common warrants exercisable at $1.20 per share, subject to stockholder approval; expire 5 years or 30 days after Week 48 data for SCY-770 in ADPKD.","CEO David Angulo purchased 108,695 shares and warrants; proceeds to be used for working capital and general corporate purposes.","Cash runway extended into mid-2029 based on current plans, including anticipated net proceeds from the private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101947,"accession_number":"0001193125-26-133250","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"SCYNEXIS acquires PXL-770 (SCY-770) from Poxel for $8M upfront, up to $188M total","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset includes direct AMPK activator PXL-770, now SCY-770, for ADPKD, with Orphan Drug Designation from FDA.","Upfront payment of $8M; potential development milestones up to $8M and commercial milestones up to $180M.","Phase 2 proof-of-concept study in ADPKD expected to start Q4 2026; early efficacy readout anticipated H2 2027.","SCY-770 has been evaluated in eight clinical trials with a favorable safety profile and targets underlying ADPKD drivers.","SCYNEXIS plans to host a conference call on March 31, 2026 at 8:30 AM ET to discuss the acquisition and corporate update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118280,"accession_number":"0001178253-25-000006","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"SCYNEXIS resolves MARIO study dispute with GSK, receives $22M payment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Binding MOU terminates Phase 3 MARIO trial for invasive candidiasis; SCYNEXIS gets $22M from GSK.","Additional $2.3M payment from GSK for wind-down and termination activities.","SCYNEXIS will transfer BREXAFEMME NDA to GSK by end of 2025; GSK plans FDA interactions in 2026 for VVC/rVVC relaunch.","Milestones and royalties for VVC and rVVC indications remain unchanged under the exclusive license agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134730,"accession_number":"0000950170-25-092176","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SCYNEXIS stockholders re-elect all seven directors, ratify Deloitte, approve say-on-pay at 2025 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with >13M votes for each; broker non-votes ~12.5M.","Ratification of Deloitte & Touche as auditor for FY 2025 passed: 25.5M for, 0.8M against.","Advisory vote on executive compensation approved: 12.4M for, 1.4M against, 0.7M abstain.","Annual meeting held June 25, 2025; all proposals passed as recommended by the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151635,"accession_number":"0000950170-25-090374","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"SCYNEXIS receives Nasdaq bid price deficiency notice; has until Dec 17 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on June 20, 2025, for bid price <$1 for 30 consecutive business days.","Has 180 calendar days until December 17, 2025, to regain compliance with minimum bid price.","May transfer to Nasdaq Capital Market for additional 180-day compliance period if needed.","Will evaluate options including potential reverse stock split to cure deficiency.","No assurance of regaining compliance; could face delisting if not cured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187473,"accession_number":"0000950170-24-122291","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SCYNEXIS enters $50M at-the-market equity facility with Cantor Fitzgerald","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with Cantor allows sale of up to $50M of common stock at SCYNEXIS's option.","Compensation to agent is 3% of gross sale proceeds under ATM offering.","Prior agreements with Cantor and Ladenburg terminated; $3.8M had been sold under those.","Offering is through effective S-3 registration statement filed Nov 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203983,"accession_number":"0000950170-24-104918","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SCYNEXIS updates corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed 8-K on Sept 10, 2024 to announce updated investor slide deck.","Exhibit 99.1 is the revised Corporate Presentation dated September 2024.","No specific financial or pipeline milestones were referenced in the filing or exhibit text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220648,"accession_number":"0000950170-24-075321","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SCYNEXIS stockholders elect all seven director nominees, approve equity plan and auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with 93.6%-96.7% of votes cast in favor.","Ratification of Deloitte & Touche as auditor for FY 2024 passed with 97.0% of votes cast.","Advisory vote on executive compensation approved with 87.1% of votes cast (excluding broker non-votes).","SCYNEXIS 2024 Equity Incentive Plan approved with 83.4% of votes cast (excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240273,"accession_number":"0000950170-24-038015","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SCYNEXIS reports FY2023 net income of $67M, driven by $130M GSK license revenue; product revenue down 80%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $67.0M ($1.40 basic EPS) vs net loss of $62.8M in FY2022; license revenue of $139M vs $103K prior year.","BREXAFEMME net product revenue fell to $1.0M (from $5.0M); cost of product revenue $15.6M including $14.6M inventory impairment from beta-lactam cross-contamination.","Cash, equivalents and investments $98.0M at Dec 31, 2023 (up from $73.5M); cash runway >2 years.","GSK deal total potential value revised to $448M (from $593M); final study reports due H1 2024 trigger $10M milestone payment.","SCY-247 IND-enabling activities advancing; Phase I initiation expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240272,"accession_number":"0000950170-24-002308","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SCYNEXIS updates corporate presentation; no material new disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted an updated investor slide presentation on its website on Jan. 5, 2024.","Exhibit 99.1 contains only a cover slide with tagline; no financial or operational details shown.","No revised guidance, business developments, or material events were reported in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240271,"accession_number":"0000950170-24-000238","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"SCYNEXIS amends GSK license after BREXAFEMME recall; milestone payments cut","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Binding MOU amends March 2023 license after beta-lactam contamination risk triggered BREXAFEMME recall and clinical hold.","Regulatory milestone cap reduced to $49M (from $70M); commercial milestone cap to $57.5M (from $115M).","Sales milestone caps lowered to $179.5M/$169.75M/$145.5M (from $242.5M), depending on relaunch date.","Up to $72.35M in development milestones, including $30M for MARIO study resumption after clinical hold lifted.","GSK already paid $90M upfront and $25M development milestone; royalty rates unchanged (mid-single to mid-teen)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257776,"accession_number":"0000950170-23-050940","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SCYNEXIS recalls BREXAFEMME; FDA places clinical hold after cross-contamination risk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Recall of BREXAFEMME (ibrexafungerp) initiated Sep 25, 2023 due to potential cross-contamination during manufacture.","FDA concurred with voluntary hold and placed clinical hold on Phase 3 MARIO and Phase 1 lactation studies.","Completed studies (FURI, CARES, VANQUISH, SCYNERGIA) unaffected; compassionate use may continue with physician benefit-risk assessment.","Pre-clinical compound SCY-247 not impacted by these developments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275125,"accession_number":"0000950170-23-049544","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SCYNEXIS recalls BREXAFEMME and pauses Phase 3 MARIO study on cross-contamination risk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GSK review found a beta-lactam drug manufactured on equipment shared with ibrexafungerp; potential cross-contamination risk.","No known contamination of ibrexafungerp and no adverse events reported; recall is out of caution.","Market recall of BREXAFEMME (ibrexafungerp tablets) and temporary hold on all clinical studies, including Phase 3 MARIO.","Mitigation strategy and resupply plan to be determined; ongoing collaboration with GSK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292535,"accession_number":"0000950170-23-029599","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["1.02","8.01"],"status":"ready","headline":"SCYNEXIS terminates $35M loan with Hercules/SVB after GSK deal; receives $25M milestone; clarifies equity vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated $35M Loan and Security Agreement with Hercules Capital and SVB on May 25, 2023, after receiving upfront payment from GSK license.","Announced $25M performance milestone from GSK on June 21, 2023, for Phase 3 MARIO study of ibrexafungerp.","Due to proxy statement ambiguity on broker non-votes, SCYNEXIS deemed 2023 Equity Incentive Plan vote not approved; will use 2014 plan and reintroduce in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292534,"accession_number":"0000950170-23-028589","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SCYNEXIS shareholders reject officer liability limit; approve equity plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to amend certificate to limit officer liability failed (12.98M for, 4.07M against, needed majority of 36.5M outstanding shares).","All seven director nominees re-elected; David Angulo received 16.50M for, 0.74M withheld.","2023 Equity Incentive Plan approved with 9.75M for, 7.21M against.","Advisory vote on executive compensation passed with 13.04M for, 3.87M against.","Ratification of Deloitte & Touche as auditor for FY2023 approved (25.16M for, 1.13M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313204,"accession_number":"0000950170-23-010748","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"SCYNEXIS licenses ibrexafungerp to GSK for $90M upfront plus up to $503M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $90M; eligible for up to $70M regulatory, $115M commercial, $242.5M sales, and $75.5M development milestones.","GSK gets exclusive rights to ibrexafungerp (BREXAFEMME) outside Greater China; SCYNEXIS retains other assets with GSK ROFN.","SCYNEXIS to repay ~$35.4M loan principal plus fees to Hercules/SVB upon receipt of upfront or by June 1, 2023.","Transaction expected to close in Q2 2023, subject to HSR waiting period expiration.","Royalties in mid-single to mid-teen percent on cumulative annual sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331725,"accession_number":"0000950170-22-023510","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SCYNEXIS Q3 net loss $29.6M ($0.62/sh), BREXAFEMME rev $1.6M; CEO to retire; PDUFA Nov 30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 net loss $29.6M vs $0.6M loss in Q3 2021; basic loss per share $0.62 vs $0.02.","BREXAFEMME net revenue $1.6M (up 23% QoQ); 5,785 total prescriptions written, up 13% vs Q2.","Cash, equivalents and short-term investments $96.1M; projected runway into Q2 2024.","CEO Marco Taglietti to retire Dec 31, 2022; David Angulo (CMO) to become CEO effective Jan 1, 2023.","PDUFA date Nov 30, 2022 for BREXAFEMME sNDA for prevention of recurrent VVC; company seeking commercialization partner."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":3567000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331724,"accession_number":"0001564590-22-034777","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2022-10-20T23:59:59+00:00","items":["1.02","5.02"],"status":"ready","headline":"SCYNEXIS CEO to retire Dec 31; appoints new CEO David Angulo and CFO Ivor Macleod","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Marco Taglietti to retire Dec 31, 2022; separation extends stock option exercise period to 4 years.","David Angulo (CMO) becomes President & CEO Jan 1, 2023; salary $565K, bonus 55%, option 165K shares, RSU 110K shares.","Ivor Macleod joins as CFO Oct 24, 2022; salary $435K, bonus 40%, option 170K shares, RSU 15K shares.","Interim CFO Larry Hoffman to step down; Chief Commercial Officer Christine Coyne to depart Nov 30, 2022.","Company to out-license BREXAFEMME, wind down promotion, focus ibrexafungerp on hospital indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349217,"accession_number":"0001564590-22-032963","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SCYNEXIS shareholders approve doubling authorized common shares to 150M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders voted to increase authorized common stock from 100M to 150M shares.","Vote results: 19,851,387 for, 4,713,947 against, 91,003 abstain.","Adjournment proposal was moot due to sufficient votes for the charter amendment.","Amendment enables future equity financing without additional shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349216,"accession_number":"0001564590-22-029405","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SCYNEXIS Q2 net loss $13.3M, revenue $1.3M; cash runway into Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["BREXAFEMME net revenue $1.3M in Q2 2022, up 86% from $0.7M in Q1.","Net loss $13.3M ($0.31/shr) vs net gain $1.7M ($0.06/shr) in Q2 2021.","Cash $118.7M at June 30, 2022; projected runway into Q1 2024.","FDA accepted sNDA for BREXAFEMME in recurrent VVC; PDUFA date Nov 30, 2022.","Total prescriptions up 29% QoQ to ~5,141; >2,200 HCPs prescribed in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":2010000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366110,"accession_number":"0001564590-22-023551","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SCYNEXIS shareholders reject proposal to increase authorized shares from 100M to 150M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; auditor Deloitte & Touche ratified.","Advisory vote on executive compensation approved (8.7M for, 1.0M against).","Proposal to increase authorized shares to 150M failed: 13.4M for, 3.0M against, but required majority of 29.2M outstanding shares.","Failure may constrain future equity financing; company cannot issue new shares without another vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366109,"accession_number":"0001564590-22-019835","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SCYNEXIS Q1 net loss $5.5M; BREXAFEMME sales $0.7M; CANDLE study positive for rVVC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.5M ($0.17/share) vs $4.7M ($0.18) in Q1 2021; product revenue $0.7M from BREXAFEMME.","Cash $95.2M at March 31; plus $42M net from April offering; runway into Q1 2024.","BREXAFEMME: ~4,000 prescriptions Q1, 1,800 HCPs; 55% commercial coverage (93M lives).","CANDLE Phase 3 met endpoint: 65.4% vs 53.1% placebo (p=0.02) for rVVC prevention; sNDA planned Q2 2022.","MARIO global Phase 3 initiated for invasive candidiasis; first patient enrollment expected Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":687000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366108,"accession_number":"0001564590-22-015284","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2022-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SCYNEXIS announces $41.9M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,333,333 shares, pre-funded warrants for 11,666,667 shares, and warrants for 15,000,000 shares at $3.00 per share.","Expected net proceeds of ~$41.9M after underwriting discount and expenses; closing on or about April 26, 2022.","Underwriters have option to purchase up to additional 2.25M shares/warrants; total proceeds could reach ~$48.2M.","Underwriters led by Guggenheim Securities and Cantor Fitzgerald; also Ladenburg Thalmann, Maxim Group, and others.","Warrants have 7-year term and exercise price of $3.45; pre-funded warrants have $0.001 exercise price and unlimited term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385601,"accession_number":"0001564590-22-012056","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SCYNEXIS reports 2021 net loss of $32.9M; BREXAFEMME revenues $1.1M in launch year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["BREXAFEMME net product revenue $1.1M full-year, $0.6M Q4; cost of product revenue $0.3M full-year.","Net loss $32.9M ($1.25/share) for FY2021 vs $55.2M ($5.15/share) in FY2020.","Cash $104.5M at year-end; projected runway into Q2 2023; plus $9.7M non-dilutive in early 2022.","Positive Phase 3 CANDLE for rVVC (65.4% vs 53.1% placebo, p=0.02); sNDA filing Q2 2022.","Initiating MARIO Phase 3 for invasive candidiasis; Orphan Medicinal Product Designation from EMA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385600,"accession_number":"0001564590-22-009487","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"SCYNEXIS receives $5M third tranche from Hercules/SVB Term Loan after CANDLE milestone","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On March 9, 2022, SCYNEXIS drew $5M under its existing $60M Term Loan with Hercules/SVB.","The tranche was triggered by positive Phase 3 CANDLE study results for ibrexafungerp.","Prior draws: $20M at closing (May 2021), $10M on FDA approval (June 2021).","Total drawn now $35M; remaining tranches subject to conditions.","Loan facility provided by Hercules Capital and Silicon Valley Bank."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385599,"accession_number":"0001564590-22-004229","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SCYNEXIS grants CEO Taglietti 87,200 RSUs and 232,000 options; CMO Angulo 51,100 RSUs, 85,000 options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Marco Taglietti receives 87,200 RSUs and options for 232,000 shares at $4.60 per share.","CMO David Angulo receives 51,100 RSUs and options for 85,000 shares at $4.60 per share.","RSUs vest 50% per year over 2 years; stock options vest in equal monthly installments over 48 months.","Grants made under the 2014 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403477,"accession_number":"0001564590-21-055929","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"SCYNEXIS reports Q3 net loss $0.6M; BREXAFEMME net sales $0.5M in first partial quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["BREXAFEMME net sales $0.5M in partial Q3; IQVIA 1,006 prescriptions in Q3, 1,100 in October.","R&D expense $4.4M (-45% YoY); SG&A $15.4M (+341% YoY driven by commercial launch costs).","Net loss $0.6M ($0.02 per basic share) vs net income $0.9M in Q3 2020.","Cash $100.1M; runway projected into 2023.","CFO Eric Francois resigning; Danforth Advisors providing interim CFO Lawrence Hoffman."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":12566000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403476,"accession_number":"0001564590-21-054267","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SCYNEXIS CFO Eric Francois to resign; Lawrence Hoffman appointed interim CFO effective Nov 19, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Eric Francois to resign effective Nov 19, 2021 to return to investment banking; will stay through transition.","Board appoints Lawrence Hoffman (CPA, JD) as interim CFO via Danforth Advisors effective Nov 19, 2021.","Hoffman will serve as principal financial and accounting officer; previously CFO at multiple biotech companies.","No family relationships or arrangements between Hoffman and company officers/directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403475,"accession_number":"0001564590-21-052818","cik":1178253,"company_name":"SCYNEXIS INC","ticker":"SCYX","form_type":"8-K","filed_at":"2021-10-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"SCYNEXIS CFO Eric Francois resigns; Danforth Advisors to provide interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Financial Officer Eric Francois notified resignation on Oct 26, 2021, effective Nov 19, 2021, to return to investment banking.","Company engaged Danforth Advisors, LLC to supply interim CFO services while a permanent replacement is found.","Francois will stay through Nov 19 to complete Q3 reporting and ensure smooth transition.","CEO Marco Taglietti thanked Francois for his role in transforming SCYNEXIS into a commercial-stage company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58592916.63175917,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}